Literature DB >> 12803506

Using cuffed and tunnelled central venous catheters as permanent vascular access for hemodialysis: a prospective study.

Ramazan Cetinkaya1, Ali Riza Odabas, Yahya Unlu, Yilmaz Selcuk, Azman Ates, Münacettin Ceviz.   

Abstract

BACKGROUND: Adequate care of a hemodialysis patient requires constant attention to the need to maintain vascular access (VA) patency. VA complications are the main cause of hospitalization in hemodialysis patients. The native arteriovenous fistula (NAVF), synthetic arteriovenous grafts fistula (GAVF) and silastic cuffed central venous catheters (CVCs) are used for permanent vascular access (PVA). CVCs are primary the method of choice for temporary access. But using this access modality is increasing more and more for PVA in elderly hemodialysis patients and when other PVA is not possible. The primary aim of this study is to investigate survivals and complications of the CVCs used for long-term VA.
METHODS: We prospectively looked at 92 CVCs (Medcomp Ash Split Cath, 14 FR x 28 cm (Little, M.A.; O'Riordan, A.; Lucey, B.; Farrell, M.; Lee, M.; Conlon, P.J.; Walshe, J.J. A prospective study of complications associated with cuffed, tunnelled hemodialysis catheters. Nephrol. Dial. Transplant. 2001, 16 (11), 2194-2200) with Dacron cuff) inserted in 85 (50 females, 35 males) chronic hemodialysis patients (the mean age: 56.6 +/- 14.1 years) from July 1999 to January 2002. The overall survival and complications were followed up. Furthermore, the patients were evaluated for demographic and clinical characteristics. Data were analysed by chi-square, Wilcoxon rank and Kaplan-Meier survival tests.
RESULTS: The median duration of CVC survival was 289 days (range: 10-720). Eleven (11.9%) CVCs were removed due to complications. In 79 (92.9%) patients, 1, in 5 (5.8%) patients, 2 and in 1 patient, 3 CVCs were inserted. Of the 85 patients, 56 have CVCs functioning. In addition, 27 (31.76%) patients have CVCs functioning for over 12 months, 17 (20%) patients have CVCs functioning for 6 months. The total incidence of CVC related infections was 0.82 episodes/1000 catheter days. Besides, thrombosis was occurred in 10 (10.8%) CVCs. The most frequent indications for CVC removal were patient death (69.4%), thrombosis (16.6%) and CVC-related infections (13.8%).
CONCLUSIONS: CVCs are primarily used for temporary access. But this study indicates that CVC may be a very useful alternative permanent vascular access for hemodialysis patients when other forms of vascular access are not available.

Entities:  

Mesh:

Year:  2003        PMID: 12803506     DOI: 10.1081/jdi-120021155

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  5 in total

Review 1.  Vascular access in elderly patients with end-stage renal disease.

Authors:  Nikolaos Bessias; Kosmas I Paraskevas; Effie Tziviskou; Vassilios Andrikopoulos
Journal:  Int Urol Nephrol       Date:  2008-09-16       Impact factor: 2.370

2.  Central venous catheters as a vascular access modality for pediatric hemodialysis.

Authors:  Fatina Ibrahim Fadel; Hesham Nabil Abdel Mooty; Hafez Mahmoud Bazaraa; Samar Mohamed Sabry
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

3.  Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial.

Authors:  David R Ward; Louise M Moist; Jennifer M MacRae; Nairne Scott-Douglas; Jianguo Zhang; Marcello Tonelli; Charmaine E Lok; Steven D Soroka; Brenda R Hemmelgarn
Journal:  Can J Kidney Health Dis       Date:  2014-07-08

4.  Transcutaneous intravascular transposition of a permanent dialysis catheter.

Authors:  Jerzy Piecuch; Maciej Wiewióra; Wojciech Jacheć; Monika Szrot; Albert Krzak
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-07-19       Impact factor: 1.195

5.  A stuck haemodialysis central venous catheter: not quite open and shut!

Authors:  Sadaf F Jafferbhoy; John R Asquith; Ravish Jeeji; Adrian Levine; Madhavan Menon; Arun D Pherwani
Journal:  J Surg Case Rep       Date:  2015-04-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.